Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of F-627 versus Neulasta for prevention of chemotherapy-induced neutropenia in breast cancer
2016-003553-15Phase 3Completed
- Sponsor
- Evive Biotech
- Start
- Dec 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of efbemalenograstim alfa in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Evive Biotech. Primary endpoint: Duration of grade 4 neutropenia in cycle 1. Started Dec 2017; status: completed.
02
Drugs
efbemalenograstim alfa
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2016-003553-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003553-15.